FORA Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

FORA Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.13M	Buy	+2,282	New	+$1.01M	0.08%	205
2025 Q4	–	Sell	-3,168	Closed	-$1.24M	–	665
2025 Q3	$1.24M	Buy	+3,168	New	+$1.32M	0.22%	122
2024 Q4	–	Sell	-9,402	Closed	-$4.37M	–	610
2024 Q3	$4.37M	Buy	9,402 +1,229	+15%	+$590K	0.51%	54
2024 Q2	$3.83M	Buy	8,173 +3,329	+69%	+$1.44M	0.47%	70
2024 Q1	$2.02M	Buy	+4,844	New	+$2.05M	0.17%	162
2023 Q4	–	Sell	-15,189	Closed	-$5.28M	–	658
2023 Q3	$5.28M	Buy	15,189 +11,257	+286%	+$3.94M	0.46%	56
2023 Q2	$1.38M	Buy	+3,932	New	+$1.32M	0.2%	134
2022 Q1	–	Sell	-5,909	Closed	-$1.3M	–	642
2021 Q4	$1.3M	Sell	5,909 -17	-0.3%	-$3.31K	0.5%	49
2021 Q3	$1.07M	Buy	+5,926	New	+$1.16M	0.27%	111
2021 Q2	–	Sell	-4,157	Closed	-$893K	–	1169
2021 Q1	$893K	Buy	+4,157	New	+$913K	0.29%	71
2020 Q2	–	Sell	-3,741	Closed	-$890K	–	1344
2020 Q1	$890K	Sell	3,741 -8,253	-69%	-$1.89M	0.19%	142
2019 Q4	$2.63M	Buy	+11,994	New	+$2.43M	0.26%	87

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

FORA Capital's VRTX Position: Q2 2026 in Review

FORA Capital opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 2,282 shares worth $1.13M. The stake represents 0.08% of the portfolio and ranks #205 among its holdings. This is a return to the name: FORA Capital previously reported a position in VRTX as recently as Q3 2025.

FORA Capital first reported a position in VRTX in Q4 2019 and has held it in 12 quarters since. The position peaked at $5.28M in Q3 2023. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

FORA Capital held 2,282 shares of Vertex Pharmaceuticals worth $1.13M as of Q2 2026.
Vertex Pharmaceuticals was a new FORA Capital position in Q2 2026.
Vertex Pharmaceuticals made up 0.08% of FORA Capital's portfolio in Q2 2026, its #205 holding.
FORA Capital first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 12 quarters since.
FORA Capital's Vertex Pharmaceuticals position peaked at $5.28M in Q3 2023.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on FORA Capital's 13F filing for Q2 2026, filed 13 Aug 2026.